Synthesis and in vitro anticancer activities of some selenadiazole derivatives

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Novel heterocyclic compounds are continuously explored for anticancer potential.
• Selenadiazole derivatives represent a class of compounds with diverse biological activities.

Purpose of the Study:

• To synthesize and evaluate novel substituted selenadiazoles for in vitro antiproliferative and cytotoxic activities.
• To assess the selectivity of these compounds against various cancer and non-tumoral cell lines.

Main Methods:

• Synthesis of fourteen substituted selenadiazole compounds.
• In vitro antiproliferative and cytotoxic assays against leukemia, colon, lung, and breast cancer cell lines.
• Selectivity assessment using non-tumoral mammary and bronchial epithelium cell lines.
• Cell cycle modulation and apoptosis induction studies on MCF-7 cells.

Main Results:

• Seven selenadiazole derivatives (2a, 2c, 2e, 2f, 2g, 3a, 3b) showed significant activity against MCF-7 breast cancer cells, with nanomolar GI50 values for 2c and 2f.
• Compound 2f exhibited a superior antitumoral profile compared to vinorelbine and paclitaxel.
• Compound 2a displayed notable antiproliferative activity across cell lines and was the most potent inducer of apoptosis in MCF-7 cells, exceeding camptothecin's effect.
• Compound 2a induced cell cycle arrest, decreasing G0/G1 phase cells and increasing S and G2/M populations, indicating mitotic arrest.

Conclusions:

• Substituted selenadiazoles, particularly derivatives 2a, 2c, 2f, exhibit promising in vitro antiproliferative and cytotoxic effects against breast cancer cells.
• Compound 2a shows significant potential as an apoptogenic agent and cell cycle modulator, warranting further investigation for cancer therapy.
• The identified selenadiazole derivatives represent valuable leads for the development of novel anticancer drugs.